Molecular Templates (MTEM) Stock Price, News & Analysis

Company Overview

Molecular Templates, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of next‐generation immunotherapies. Utilizing its proprietary Evolution Platform—an advanced directed evolution protein engineering system—the company designs targeted protein therapeutics aimed at improving efficacy and safety profiles for patients with cancer. Molecular Templates leverages its platform to discover novel fusion proteins that redirect and enhance immune responses against tumor cells.

The company’s lead investigational candidate, MT-6402, combines checkpoint inhibition with a tumor‐localized cytokine payload and is currently undergoing clinical evaluation in multiple solid tumor indications. Beyond MT-6402, Molecular Templates is advancing a pipeline of targeted superantigens and cytokine fusion proteins, each engineered to selectively engage and activate immune cells within the tumor microenvironment while minimizing systemic exposure and associated toxicities.

Founded in 2011 and headquartered in Austin, Texas, Molecular Templates was established to translate cutting‐edge protein engineering innovations into therapeutic realities. The company collaborates with academic research centers, clinical partners, and contract manufacturing organizations to support its translational research efforts and to scale up production for clinical trials. Its development programs span the United States and Europe, reflecting a commitment to broad patient access and global regulatory engagement.

Under the leadership of President and CEO Joe Pantginis, who brings extensive experience in biotechnology R&D and corporate development, Molecular Templates has built a seasoned management team and board of directors with deep expertise in immuno‐oncology and molecular engineering. Supported by a cross‐functional team of scientists, clinicians, and regulatory specialists, the company is dedicated to advancing its novel therapeutic candidates through the clinic toward potential regulatory approval.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 5.43 million shs
• Market Capitalization: $1 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MTEM Stock Analysis - Frequently Asked Questions

How were Molecular Templates' earnings last quarter?

Molecular Templates, Inc. (NASDAQ:MTEM) posted its earnings results on Monday, November, 15th. The biotechnology company reported ($8.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.67) by $2.43. The biotechnology company earned $2.38 million during the quarter, compared to the consensus estimate of $15.69 million. Molecular Templates had a negative trailing twelve-month return on equity of 260.50% and a negative net margin of 61.35%.

When did Molecular Templates' stock split?

Molecular Templates's stock reverse split on the morning of Monday, August 14th 2023.The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Templates investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Alibaba Group (BABA) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 7/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MTEM
• CIK: 1183765
• Web: www.mtem.com
• Phone: (512) 869-1555
• Fax: 650-474-2529
• Employees: 260
• Year Founded: 2009

Profitability

• EPS (Trailing Twelve Months): ($2.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.12 million
• Net Margins: -61.35%
• Pretax Margin: -61.39%
• Return on Equity: -260.50%
• Return on Assets: -46.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.56
• Quick Ratio: 1.56

Sales & Book Value

• Annual Sales: $23.48 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.78 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 6,584,000
• Free Float: 5,669,000
• Market Cap: $1 thousand
• Optionable: No Data
• Beta: 1.53